Home
Bionovis

Bionovis Market Share Analysis for August 2026

Área de atuação As parcerias permitem que a Bionovis receba tecnologia e treinamento de ponta e se capacite, em curto prazo, para atuar na produção e comercialização de medicamentos biológicos e biossimilares de alta complexidade. A Bionovis atua na prospecção de produtos e recursos científicos para licenciamento e transferência de tecnologia e está habilitada para […]

Industry: N/A

Domainbionovis.com.br

Year Founded2012

Employees201 - 500

Annual Revenue--

Bionovis

Bionovis (including company regionals)

bionovis.com.br

See more website traffic and engagement information

Total visits to Bionovis's top domains

Understand Bionovis market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

bionovis.com.br3K

See more with Sales Intelligence

Avg. visit duration in Bionovis's top domains

Analyze Bionovis engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

bionovis.com.br00:00:57

See more with Sales Intelligence

Avg. pageviews on Bionovis's top domains

See how Bionovis keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

bionovis.com.br1.63

See more with Sales Intelligence

Bionovis top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Bionovis

These are the website technologies, by industry, used by Bionovis top domains

Widget (7)

Twemoji

Advertising (3)

DoubleClick

Marketing (3)

Google Marketing Platform

Content Management System (2)

WordPress

More Technologies

7

See all

News & Signals from Bionovis

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBiocon Limited partnered with Bionovis on Sep 8th '26.Biocon Limited has secured a 10-year supply contract in Brazil for Pertuzumab, a monoclonal antibody used to treat HER2-positive breast cancer, after signing a partnership agreement with Brazilian public pharmaceutical laboratory Bahiafarma and biotechnology company Bionovis.

NewsBahiafarma partnered with Bionovis on Sep 8th '26.The partnership with Bahiafarma and Bionovis gives Biocon 100% allocation under Brazil's 10-year Productive Development Partnership programme for Pertuzumab.

NewsFiocruz partners with Bionovis SA.In pharmaceuticals, Farmanguinhos/Fiocruz and Biocon Pharma concluded an MoU for joint R&D in strategic medicines - including oncology and rare diseases - for public health systems, while BahiaFarma, Biocon Biologics and Bionovis signed a commitment agreement for the productive development of Pertuzumab, a HER-2 metastatic breast cancer treatment, covering an estimated 72,000 patients annually at a procurement value of BRL 503.4 million.